JP2022506503A5 - - Google Patents
Info
- Publication number
- JP2022506503A5 JP2022506503A5 JP2021523902A JP2021523902A JP2022506503A5 JP 2022506503 A5 JP2022506503 A5 JP 2022506503A5 JP 2021523902 A JP2021523902 A JP 2021523902A JP 2021523902 A JP2021523902 A JP 2021523902A JP 2022506503 A5 JP2022506503 A5 JP 2022506503A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- antisense strand
- dsrna agent
- sense strand
- strand
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024129696A JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758094P | 2018-11-09 | 2018-11-09 | |
| US62/758,094 | 2018-11-09 | ||
| PCT/US2019/059818 WO2020097044A1 (en) | 2018-11-09 | 2019-11-05 | Modified double stranded oligonucleotides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129696A Division JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022506503A JP2022506503A (ja) | 2022-01-17 |
| JPWO2020097044A5 JPWO2020097044A5 (https=) | 2022-09-20 |
| JP2022506503A5 true JP2022506503A5 (https=) | 2022-09-20 |
| JP7536007B2 JP7536007B2 (ja) | 2024-08-19 |
Family
ID=70612465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523902A Active JP7536007B2 (ja) | 2018-11-09 | 2019-11-05 | 修飾二重鎖オリゴヌクレオチド |
| JP2024129696A Pending JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129696A Pending JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12600965B2 (https=) |
| EP (1) | EP3877524A4 (https=) |
| JP (2) | JP7536007B2 (https=) |
| AU (2) | AU2019376628B2 (https=) |
| CA (1) | CA3118537A1 (https=) |
| WO (1) | WO2020097044A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3216595A1 (en) | 2013-03-14 | 2014-10-02 | Kevin Fitzgerald | Complement component c5 irna compositions and methods of use thereof |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| CA3118537A1 (en) * | 2018-11-09 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Modified double stranded oligonucleotides |
| KR20220115946A (ko) * | 2019-11-13 | 2022-08-19 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물 |
| MX2023008469A (es) * | 2021-01-22 | 2023-11-22 | Alnylam Pharmaceuticals Inc | Oligonucleotidos de doble hebra modificados. |
| WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| WO2022212231A2 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| KR20240067943A (ko) | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| EP4493570A2 (en) | 2022-03-16 | 2025-01-22 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
| KR20240163743A (ko) | 2022-03-28 | 2024-11-19 | 엠피리코 인크. | 변형된 올리고뉴클레오티드 |
| EP4662311A2 (en) * | 2023-02-09 | 2025-12-17 | Alnylam Pharmaceuticals, Inc. | Reversir molecules and methods of use thereof |
| WO2026046152A1 (zh) * | 2024-08-26 | 2026-03-05 | 倍臻生物技术（苏州）有限公司 | 修饰的双链核糖核酸及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2652134B1 (en) * | 2010-12-17 | 2017-03-01 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
| EP2780454A2 (en) | 2011-11-18 | 2014-09-24 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| HUE048622T2 (hu) | 2011-11-18 | 2020-08-28 | Alnylam Pharmaceuticals Inc | RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| KR102486617B1 (ko) | 2013-05-22 | 2023-01-12 | 알닐람 파마슈티칼스 인코포레이티드 | Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법 |
| TW201610151A (zh) | 2013-09-23 | 2016-03-16 | 阿尼拉製藥公司 | 治療或預防與甲狀腺素運載蛋白相關疾病之方法 |
| TWI768330B (zh) | 2013-10-04 | 2022-06-21 | 美國西奈山伊坎醫學院 | 抑制alas1基因表現的組合物及方法 |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| TWI864340B (zh) | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| TWI710633B (zh) | 2014-11-10 | 2020-11-21 | 美商阿尼拉製藥公司 | Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法 |
| HK1244843A1 (zh) | 2014-11-17 | 2018-08-17 | Alnylam Pharmaceuticals, Inc. | 载脂蛋白c3(apoc3)irna组合物及其使用方法 |
| WO2016085852A1 (en) | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| EA201792263A1 (ru) | 2015-04-13 | 2018-08-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| CN108138182B (zh) | 2015-07-31 | 2022-08-19 | 阿尔尼拉姆医药品有限公司 | 甲状腺素运载蛋白(TTR)iRNA组合物及其治疗或预防TTR相关疾病的使用方法 |
| CN118697894A (zh) | 2015-08-25 | 2024-09-27 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
| US11260134B2 (en) | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
| TW202313978A (zh) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| KR102645243B1 (ko) | 2016-11-23 | 2024-03-11 | 알닐람 파마슈티칼스 인코포레이티드 | 표적외 효과가 감소된 변형 rna 작용제 |
| AU2017376950B2 (en) | 2016-12-16 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions |
| IL269927B2 (en) | 2017-04-18 | 2025-04-01 | Alnylam Pharmaceuticals Inc | Methods of treating patients with hepatitis B virus infection |
| AU2018301477A1 (en) | 2017-07-13 | 2020-02-27 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof |
| JP7507093B2 (ja) | 2018-03-21 | 2024-06-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法 |
| CA3106701A1 (en) | 2018-08-13 | 2020-02-20 | Alnylam Pharmaceuticals, Inc. | Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof |
| CA3118537A1 (en) * | 2018-11-09 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Modified double stranded oligonucleotides |
-
2019
- 2019-11-05 CA CA3118537A patent/CA3118537A1/en active Pending
- 2019-11-05 WO PCT/US2019/059818 patent/WO2020097044A1/en not_active Ceased
- 2019-11-05 US US17/291,775 patent/US12600965B2/en active Active
- 2019-11-05 AU AU2019376628A patent/AU2019376628B2/en active Active
- 2019-11-05 JP JP2021523902A patent/JP7536007B2/ja active Active
- 2019-11-05 EP EP19882543.2A patent/EP3877524A4/en active Pending
-
2024
- 2024-08-06 JP JP2024129696A patent/JP2024149701A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259857A patent/AU2025259857A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506503A5 (https=) | ||
| JP2005517452A5 (https=) | ||
| JP2022003044A5 (https=) | ||
| JP2006502694A5 (https=) | ||
| JP2019141097A5 (https=) | ||
| JP2018512110A5 (https=) | ||
| JP2005524393A5 (https=) | ||
| JP2009060893A5 (https=) | ||
| JP2018512041A5 (https=) | ||
| JP2020500929A5 (https=) | ||
| JP2005517430A5 (https=) | ||
| JP2005517432A5 (https=) | ||
| JP2005517438A5 (https=) | ||
| JP2017079776A5 (https=) | ||
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| WO2015051366A3 (en) | Novel formats for organic compounds for use in rna interference | |
| JP2024105284A5 (https=) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| JP2016116520A5 (https=) | ||
| CA2457528A1 (en) | Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) | |
| WO2005014782A3 (en) | Double-stranded ribonucleic acid with increased effectiveness in an organism | |
| WO2004029212A3 (en) | In vivo gene silencing by chemically modified and stable sirna | |
| WO2009054551A3 (en) | Lipid-modified double-stranded rna having potent rna interference effect | |
| JP2013226147A5 (https=) | ||
| JP2015518714A5 (https=) |